CALL/EVOTEC/16/0.1/20.12.24 Share Price

Warrant

DE000GQ6DFS5

Market Closed - BOERSE MUENCHEN 19:25:18 01/07/2024 BST
0.044 EUR +57.14% Intraday chart for CALL/EVOTEC/16/0.1/20.12.24
Current month+57.14%
1 month+62.96%
Date Price Change
01/07/24 0.044 +57.14%
28/06/24 0.028 +3.70%
27/06/24 0.027 -3.57%
26/06/24 0.028 0.00%
25/06/24 0.028 -9.68%

Real-time BOERSE MUENCHEN

Last update July 01, 2024 at 07:25 pm

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying EVOTEC SE
Issuer Goldman Sachs
WKN GQ6DFS
ISINDE000GQ6DFS5
Date issued 28/09/2023
Strike 16
Maturity 20/12/2024 (172 Days)
Parity 10 : 1
Emission price 0.47
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 0.761
Lowest since issue 0.024
Delta0.21x
Omega 4.278
Premium82.26x
Gearing20.5x
Moneyness 0.5638
Difference Strike 6.98
Difference Strike %+43.63%
Spread 0.01
Spread %20.41%
Theoretical value 0.0440
Implied Volatility 75.67 %
Total Loss Probability 90.83 %
Intrinsic value 0.000000
Present value 0.0440
Break even 16.44 €
Theta-0x
Vega0x
Rho0x

Company Profile

Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Sector
-
More about the company

Ratings for Evotec SE

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Consensus: Evotec SE

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
9.02 EUR
Average target price
20.79 EUR
Spread / Average Target
+130.49%
Consensus